Results 81 to 90 of about 70,014 (324)

Hyperlipidemia in Equine, Canine and Feline

open access: yes, 2022
Hyperlipidemia is defined by the presence of elevated lipid concentrations in blood and are typically associated with periods of negative energy balance and physiologic stress.
Hyperlipidemia in Equine, Canine and Feline
core   +1 more source

SCREENING FOR HYPERCHOLESTEROLEMIA IN 5 YEAR OLD CHILDREN IN SLOVENIA

open access: yesZdravniški Vestnik, 2003
Background. Cardiovascular diseases represent the most frequent cause of morbidity and mortality in developed countries. Blood cholesterol concentration influences the progression of atherosclerosis and most developed countries started programs for early
Nataša Uršič-Bratina   +6 more
doaj  

Statin-Associated Muscle Adverse Events : Update for clinicians

open access: yesSultan Qaboos University Medical Journal, 2016
Statins are potent medications which reduce low-density lipoprotein cholesterol (LDL-C) levels. Their efficacy in cardiovascular risk reduction is well established and indications for their use are expanding.
Maha A. Al-Mohaissen   +3 more
doaj   +1 more source

Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES: A Single‐Arm Clinical Trial

open access: yesAnnals of Neurology, EarlyView.
Objective To evaluate the effectiveness and safety of ocrelizumab in self‐identified black and Hispanic people with relapsing multiple sclerosis. Methods The Characterization of Ocrelizumab in Minorities with Multiple Sclerosis (CHIMES) trial, a prospective, open‐label, single‐arm, phase 4 study, intentionally recruited underrepresented populations in ...
Lilyana Amezcua   +16 more
wiley   +1 more source

Unveiling Endotypes in Systemic Lupus Erythematosus Through Multiomic Analysis: Insights Into Cardiovascular and Renal Complications

open access: yesArthritis &Rheumatology, EarlyView.
Objective Systemic lupus erythematosus (SLE) shows clinical and molecular heterogeneity, and cardiovascular (CV) complications and lupus nephritis (LN) remain leading causes of morbidity and mortality. This study investigated whether omic profiling can reveal molecular endotypes linked to these outcomes.
Tomás Cerdó   +84 more
wiley   +1 more source

Associations of Overweight, Obesity, and Underweight With High Serum Total Cholesterol Level Over 30 Years Among the Japanese Elderly: NIPPON DATA 80, 90, and 2010

open access: yesJournal of Epidemiology, 2019
Background: The trend of association between overweight and high serum total cholesterol (TC) among the elderly is unclear. In addition, there is little evidence of risk of underweight for high TC.
Yosuke Shibata   +15 more
doaj   +1 more source

Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration

open access: yesArthritis &Rheumatology, EarlyView.
Objective To develop, externally validate, and simplify a machine learning model to predict remission between 6 and 24 months in patients with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitors, JAK inhibitors, interleukin‐6 inhibitors, abatacept, or rituximab using data from 11 international registries in the JAK‐pot collaboration ...
Zubeyir Salis   +22 more
wiley   +1 more source

Factors Associated with Goal Achievement in Patients with Dyslipidemia in Primary Care

open access: yesIatreia
Introduction: Dyslipidemia promotes atherosclerotic disease. A strategy to reduce this risk is to achieve low-density lipoprotein (LDL) goals; however, these are often not attained.
Pinto-González, Gustavo   +2 more
doaj   +1 more source

Statins: a tale of two pathways—cardiovascular savior, renal ineffectual [PDF]

open access: yesPrecision and Future Medicine
Statins are effective in improving outcomes in the general population. However, in patients with chronic kidney disease (CKD), clinical outcomes and therapeutic approaches require careful interpretation from multiple perspectives.
Jihyun Yang
doaj   +1 more source

Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo‐Controlled Phase 3 Trials

open access: yesArthritis &Rheumatology, EarlyView.
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy